NeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Denshi in Japan
2017年8月3日 - 11:13PM
ビジネスワイヤ(英語)
NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement
with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is
NeuroMetrix’ rapid, accurate, and quantitative point-of-care test
to detect diabetic peripheral neuropathy. Diabetes is a serious
health issue in Japan with a prevalence of 5.7% of the adult
population or over 7 million people. DPNCheck received regulatory
clearance and was commercially launched in Japan during 2014.
Distribution was handled by Omron Healthcare until the sale of its
hospital medical products business to Fukuda Denshi in late 2016.
This new distribution arrangement will complete the product
transition to Fukuda Denshi and represents an opportunity to
accelerate local marketing efforts. DPNCheck is currently being
introduced to Fukuda Denshi’s domestic sales force who will handle
the product through their national sales network of over 230
locations.
“Omron Healthcare did an excellent job of developing DPNCheck’s
scientific and clinical credibility among leading academic and
practicing physicians in Japan,” said Shai N. Gozani, M.D., Ph.D.,
President and CEO of NeuroMetrix, Inc. “Multiple clinical studies
coordinated by Omron confirmed the effectiveness of DPNCheck in the
Japanese population, a factor crucial to local marketing efforts.
We look forward to working with Fukuda Denshi to build upon this
clinical foundation to expand the Japan market for DPNCheck.”
“We appreciate the important role of DPNCheck in early detection
of diabetic peripheral neuropathy and the avoidance or management
of related health complications,” said Hiroyuki Babasaki, Senior
Operating Officer of Fukuda Denshi. “This unique technology has the
potential to meet the needs of medical facilities in Japan and we
believe the synergy between our distinct product portfolio and the
DPNCheck will bring great opportunities and positive impact to our
business.”
About DPNCheck
NC-stat DPNCheck is a rapid, accurate and quantitative
point-of-care test to detect diabetic peripheral neuropathy, or
DPN, at an early stage allowing physicians to select appropriate
treatment. DPN is the most common complication of diabetes,
affecting over half of people with diabetes. DPN causes significant
morbidity including pain, increased risk of falling in the elderly,
and is the primary trigger for diabetic foot ulcers which may
require lower extremity amputations. For product information
visit DPNCheck.com.
About Fukuda Denshi
Fukuda Denshi, headquartered in Tokyo and founded in 1939, is a
leading medical device company with a product focus in cardiology
instrumentation, patient monitoring, ultrasound technologies, as
well as home medical care. It is headquartered in Tokyo where it
maintains its R&D and principal manufacturing facilities which
support its worldwide sales network. For more information on Fukuda
Denshi, please visit fukuda.com
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining neurostimulation and digital medicine
to address chronic health conditions including chronic pain, sleep
disorders, and diabetes. The company's lead product is Quell®, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from
the Harvard-MIT Division of Health Sciences and
Technology in 1996. For more information, please
visit NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170803005852/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761Chief Financial
Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NUROW)
過去 株価チャート
から 9 2024 まで 10 2024
NeuroMetrix (NASDAQ:NUROW)
過去 株価チャート
から 10 2023 まで 10 2024